Strategies for Manipulating T Cells in Cancer Immunotherapy
10.4062/biomolther.2021.180
- Author:
Hyang-Mi LEE
1
Author Information
1. College of Pharmacy, Dongduk Women’s University, Seoul 02748, Republic of Korea
- Publication Type:Review
- From:Biomolecules & Therapeutics
2022;30(4):299-308
- CountryRepublic of Korea
- Language:English
-
Abstract:
T cells are attractive targets for the development of immunotherapy to treat cancer due to their biological features, capacity of cytotoxicity, and antigen-specific binding of receptors. Novel strategies that can modulate T cell functions or receptor reactivity provide effective therapies, including checkpoint inhibitor, bispecific antibody, and adoptive transfer of T cells transduced with tumor antigen-specific receptors. T cell-based therapies have presented successful pre-clinical/clinical outcomes despite their common immune-related adverse effects. Ongoing studies will allow us to advance current T cell therapies and develop innovative personalized T cell therapies. This review summarizes immunotherapeutic approaches with a focus on T cells. Anti-cancer T cell therapies are also discussed regarding their biological perspectives, efficacy, toxicity, challenges, and opportunities.
